Arno Groenewoud
Chief Financial Officer (since 2024)
Date of birth: October 9, 1971
Nationality: Dutch
Education: University of Amsterdam.
Professional background: PricewaterhouseCoopers , Actelion (2014-2017), Head of Global Finance & Procurement, Idorsia (2017-2024).
Martine Clozel
Executive Vice President, Chief Scientific Officer (since 2017)
Date of birth: December 27, 1955
Nationality: Swiss and French
Education: MD, specialization in pediatrics and in neonatal intensive care, educated at the University of Nancy, France; further training in physiology and pharmacology at McGill University, Montreal, Canada, and at the University of California, San Francisco, US.
Professional background: Assistant professor, Neonatology; Scientific expert, leader of drug discovery projects, F. Hoffmann-La Roche Ltd; Co-founder and Head of Drug Discovery, Pharmacology & Preclinical Development, Actelion (1997–2009); Chief Scientific Officer, Actelion (2009–2017).
Awards: Officer of the Legion of Honour in France; Doctor honoris causa from the Swiss Federal Institute of Technology Lausanne (EPFL); Prix Suisse 2022 awarded by Initiative Switzerland; Doctor honoris causa from the University of Basel.
Other functions: Vice Chair of Board of Trustees, Marcel Benoist Foundation.
Julien Gander
Group General Counsel
Date of birth: 1979
Nationality: Swiss
Education: Master of law (LL.M.), University of Cambridge, Trinity Hall, United Kingdom; Lic. iur., University of Fribourg, Switzerland; 2006 Bar admission, Canton of Bern.
Professional background: 2007-2012 Associate in Corporate/M&A team at Homburger AG; 2012-2016 Director Legal (heading Corporate Law), Member of Legal & IP Leadership Team, Group Risk Officer at Lonza AG; 2016-2022 General Counsel, Secretary of the Board and Compliance Officer at Molecular Partners AG.
Other functions: Secretary of the Board of Idorsia Ltd., member of Idorsia Pharmaceuticals Ltd Board.
Alberto Gimona
Executive Vice President, Head of Global Clinical Development (since 2022)
Date of birth: March 28, 1960
Nationality: Italian
Education: MD, Pisa University, Italy; Postgraduate course in Clinical Pharmacology, Milan University, Italy
Professional background: Various clinical and therapeutic area leadership positions at Rhône-Poulenc Rorer, Novartis, Serono, Merck Serono; Head of Clinical Science, Actelion (2011–2017); Head of Clinical Development, Actelion/Janssen (2017–2019); Head of Therapeutic Areas Unit, Idorsia (2019–2022).
Other functions: None
André C. Muller
Chief Executive Officer (since 2024)
Date of birth: October 30, 1963
Nationality: French
Education: Master’s degree in Business Administration from EMLYON Business School, Lyon, France.
Professional background: Held various financial positions at Pierre Fabre SA, an international pharmaceutical and dermo-cosmetic company, serving as CFO from 2002 (1994–2011); CFO, Actelion (2013–2017); CFO, Idorsia (2017-2024).
Other Group functions: Member of the Board of Idorsia Pharmaceuticals Ltd
Other functions: Member of the Board of Directors of the non-listed company Chiron Investments AG.
Chief Science Officer
Martine Clozel
Chief Financial Officer
Arno Groenewoud
Chief Executive Officer
André C. Muller
Group General Counsel
Julian Gander
Head of Global Clinical Development & Medical Affairs
Alberto Gimona
Group General Counsel
Julian Gander
